The Real Cost of DMEPOS Accreditation: Why Small Suppliers Struggle to Justify It

Recent Trends

Over the past several years, the durable medical equipment (DME) supplier landscape has shifted noticeably. Large national chains continue to consolidate market share, while independent and small-volume suppliers face mounting administrative pressure. One of the most frequently cited stress points is DMEPOS accreditation — the mandatory third-party certification required to bill Medicare for most DME items.

Industry observers note that the number of newly accredited small suppliers has plateaued, even as Medicare enrollment among beneficiaries grows. The trend suggests that the perceived burden of accreditation, rather than the demand for equipment, is shaping the market’s entry dynamics. Small suppliers increasingly describe accreditation not as a one-time hurdle, but as an ongoing operational tax on their time and margins.

Background

DMEPOS accreditation was broadly introduced to combat fraud, waste, and abuse in the Medicare program. Suppliers must undergo a rigorous on-site survey, submit extensive documentation, and demonstrate compliance with quality standards set by recognized accrediting bodies. The process is intended to ensure that beneficiaries receive safe, appropriate equipment from legitimate businesses.

Accreditation is not a single event. It requires:

• An initial application and readiness review, often involving months of preparation.
• A physical site inspection covering everything from storage conditions to customer intake procedures.
• Ongoing compliance monitoring, including periodic re-surveys on cycles that can range from one to three years.
• Continuous staff training and documentation updates to remain aligned with changing billing and safety rules.

For a solo owner-operator or a small family-run supplier, these requirements overlap directly with daily operations. Unlike larger firms that employ dedicated compliance staff, small suppliers typically assign these duties to the owner or a single office manager who must still manage inventory, deliveries, and patient care.

User Concerns

The most common complaints from small suppliers center on three distinct areas: direct costs, hidden labor, and reimbursement timing.

Direct and Indirect Costs

Accreditation fees themselves vary widely depending on the accrediting body, the complexity of the supplier’s product line, and the number of locations. Practical estimates for initial accreditation often fall in the low thousands of dollars, with renewal fees recurring on a periodic basis. However, suppliers frequently report that preparation costs — such as hiring consultants, upgrading facilities, and purchasing compliance software — can multiply the base fee by a significant factor.

Staff Time and Opportunity Cost

Small suppliers rarely have the luxury of a compliance department. Time spent compiling evidence of compliance, scheduling inspections, and responding to corrective action plans is time not spent on revenue-generating activity. For a two-person shop, the opportunity cost can easily eclipse the monetary fee.

Reimbursement Uncertainty

Even after achieving accreditation, small suppliers face unstable reimbursement. Medicare’s competitive bidding program and frequent policy updates create a situation where accreditation guarantees the right to bill, but not the ability to earn a reasonable margin. Suppliers report that the accreditation investment becomes harder to justify when payers continually reduce allowable amounts or delay claim processing.

Likely Impact

The combination of high administrative burden and uncertain revenue has several probable consequences for the DME sector.

• Market consolidation: Small suppliers may exit the Medicare market entirely, choosing to serve only cash-paying or commercially insured customers, or selling their patient bases to larger organizations.
• Reduced patient access: Rural and underserved areas, which often rely on a single independent supplier, may see longer wait times for equipment or a complete loss of local service.
• Higher prices for non-Medicare customers: To offset accreditation and compliance costs, suppliers may shift overhead onto private-pay or commercial insurance pricing, raising costs for patients outside Medicare.
• Increased use of accreditation consultants: A cottage industry of compliance advisors has grown, but this service is an added expense that further widens the gap between large and small suppliers.

The situation creates a paradox: accreditation was designed to protect beneficiaries, but if it pushes small, patient-centered suppliers out of the market, those same beneficiaries may face worse outcomes due to reduced competition and convenience.

What to Watch Next

Several indicators will determine whether the accreditation burden eases or becomes more severe in the near term.

• Accreditation standards reform: Watch for any rulemaking that streamlines the survey process or creates a tiered accreditation system based on supplier size or product complexity.
• CMS policy adjustments: Any change to Medicare’s fee schedule, competitive bidding rules, or documentation requirements will directly affect whether small suppliers can sustain the accreditation investment.
• Alternative certification models: Some states and private payers are experimenting with lighter-touch licensure pathways that may partially substitute for full DMEPOS accreditation, potentially giving small suppliers a new route to market.
• Technology adoption: The maturity of cloud-based compliance platforms and remote auditing tools could reduce the cost of maintaining accreditation, but only if accrediting bodies accept digital-first evidence collection.
• Legislative activity: Monitoring pending bills that address Medicare administrative simplification will provide clues about whether Congress views small supplier attrition as a problem worth solving.

For now, the central question remains unresolved: whether DMEPOS accreditation serves as a meaningful quality safeguard or as an unintentional barrier to entry. Small suppliers will continue to weigh the real, recurring costs of accreditation against the shrinking and unpredictable benefits of Medicare participation. The direction of that calculation will likely shape the geographic accessibility of DME for years to come.